RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED

Clinical trials for RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED explained in plain language.

Never miss a new study

Get alerted when new RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED trials appear

Sign up with your email to follow new studies for RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for kids with aggressive brain tumors: experimental drug trial opens

Disease control Recruiting now

This early-stage trial is testing a new drug called CBL0137 in children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma have come back or stopped responding to standard treatments. The main goals are to find the safest dose and see if the drug can help …

Matched conditions: RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED

Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED

Get alerted when new RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED trials appear

New hope for kids with aggressive brain tumors: experimental drug trial opens